The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated:
In one of the biggest startups ever, Xaira Therapeutics has launched with more than $1 billion from investors. The financing, according to BioWorld records, is roughly equivalent to Roivant Sciences Inc.’s $1.1 billion raise in August 2017 and Galderma Inc.’s $1 billion private placement in June 2023. Xaira said it plans to leverage advanced machine learning research and expansive data generation to power new models for developing new therapeutics.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators potentially useful for the treatment of epilepsy and depression.
The Chinese National Institutes of Pharmaceutical Research & Development has divulged nitrogen-containing heterocyclic compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Ono Pharmaceutical Co. Ltd. has synthesized monoacylglycerol lipase ABHD6 inhibitors reported to be useful for the treatment of cancer, pain, neurological, inflammatory, autoimmune and metabolic diseases.
Shanghai Jemincare Pharmaceuticals Co. Ltd. has disclosed phosphorus-containing compounds acting as androgen receptor antagonists reported to be useful for the treatment of cancer, alopecia, acne, hirsutism and more.
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Prism Biolab Co. Ltd. to generate novel oncology drug candidates.